Literature DB >> 27147669

Pathophysiology of gadolinium-associated systemic fibrosis.

Brent Wagner1, Viktor Drel2, Yves Gorin2.   

Abstract

Systemic fibrosis from gadolinium-based magnetic resonance imaging contrast is a scourge for the afflicted. Although gadolinium-associated systemic fibrosis is a rare condition, the threat of litigation has vastly altered clinical practice. Most theories concerning the etiology of the fibrosis are grounded in case reports rather than experiment. This has led to the widely accepted conjecture that the relative affinity of certain contrast agents for the gadolinium ion inversely correlates with the risk of succumbing to the disease. How gadolinium-containing contrast agents trigger widespread and site-specific systemic fibrosis and how chronicity is maintained are largely unknown. This review highlights experimentally-derived information from our laboratory and others that pertain to our understanding of the pathophysiology of gadolinium-associated systemic fibrosis.
Copyright © 2016 the American Physiological Society.

Entities:  

Keywords:  NADPH oxidase; fibrosis; gadolinium; nephrogenic fibrosing dermopathy; skin diseases

Mesh:

Substances:

Year:  2016        PMID: 27147669      PMCID: PMC4967166          DOI: 10.1152/ajprenal.00166.2016

Source DB:  PubMed          Journal:  Am J Physiol Renal Physiol        ISSN: 1522-1466


  101 in total

Review 1.  Myofibroblasts and mechano-regulation of connective tissue remodelling.

Authors:  James J Tomasek; Giulio Gabbiani; Boris Hinz; Christine Chaponnier; Robert A Brown
Journal:  Nat Rev Mol Cell Biol       Date:  2002-05       Impact factor: 94.444

2.  Nephrogenic systemic fibrosis among liver transplant recipients: a single institution experience and topic update.

Authors:  M Maloo; P Abt; R Kashyap; D Younan; M Zand; M Orloff; A Jain; A Pentland; G Scott; A Bozorgzadeh
Journal:  Am J Transplant       Date:  2006-06-19       Impact factor: 8.086

3.  Risk for nephrogenic systemic fibrosis with gadoteridol (ProHance) in patients who are on long-term hemodialysis.

Authors:  Robert F Reilly
Journal:  Clin J Am Soc Nephrol       Date:  2008-02-20       Impact factor: 8.237

4.  Efficiency, thermodynamic and kinetic stability of marketed gadolinium chelates and their possible clinical consequences: a critical review.

Authors:  Marc Port; Jean-Marc Idée; Christelle Medina; Caroline Robic; Monique Sabatou; Claire Corot
Journal:  Biometals       Date:  2008-03-15       Impact factor: 2.949

5.  Nephrogenic systemic fibrosis: evidence for oxidative stress and bone marrow-derived fibrocytes in skin, liver, and heart lesions using a 5/6 nephrectomy rodent model.

Authors:  Brent Wagner; Chunyan Tan; Jeffrey L Barnes; Seema Ahuja; Thomas L Davis; Yves Gorin; Fabio Jimenez
Journal:  Am J Pathol       Date:  2012-10-04       Impact factor: 4.307

Review 6.  Biochemical safety profiles of gadolinium-based extracellular contrast agents and nephrogenic systemic fibrosis.

Authors:  Hale Ersoy; Frank J Rybicki
Journal:  J Magn Reson Imaging       Date:  2007-11       Impact factor: 4.813

7.  Preclinical investigation to compare different gadolinium-based contrast agents regarding their propensity to release gadolinium in vivo and to trigger nephrogenic systemic fibrosis-like lesions.

Authors:  Martin A Sieber; Philipp Lengsfeld; Thomas Frenzel; Sven Golfier; Heribert Schmitt-Willich; Fred Siegmund; Jakob Walter; Hanns-Joachim Weinmann; Hubertus Pietsch
Journal:  Eur Radiol       Date:  2008-06-11       Impact factor: 5.315

Review 8.  Circulating fibrocytes: collagen-secreting cells of the peripheral blood.

Authors:  Timothy E Quan; Shawn Cowper; Sou-Pan Wu; Linda K Bockenstedt; Richard Bucala
Journal:  Int J Biochem Cell Biol       Date:  2004-04       Impact factor: 5.085

9.  Nephrogenic systemic fibrosis: a population study examining the relationship of disease development to gadolinium exposure.

Authors:  Aneet Deo; Mitchell Fogel; Shawn E Cowper
Journal:  Clin J Am Soc Nephrol       Date:  2007-02-07       Impact factor: 8.237

10.  Deficiency of NOX1 or NOX4 Prevents Liver Inflammation and Fibrosis in Mice through Inhibition of Hepatic Stellate Cell Activation.

Authors:  Tian Lan; Tatiana Kisseleva; David A Brenner
Journal:  PLoS One       Date:  2015-07-29       Impact factor: 3.240

View more
  18 in total

1.  Intravoxel Incoherent Motion (IVIM) Diffusion Weighted Imaging (DWI) in the Periferic Prostate Cancer Detection and Stratification.

Authors:  Filippo Pesapane; Francesca Patella; Enrico Maria Fumarola; Silvia Panella; Anna Maria Ierardi; Giovanni Guido Pompili; Giuseppe Franceschelli; Salvatore Alessio Angileri; Alberto Magenta Biasina; Gianpaolo Carrafiello
Journal:  Med Oncol       Date:  2017-01-31       Impact factor: 3.064

2.  Nephrotoxicity of gadolinium-based contrast in the setting of renal artery intervention: retrospective analysis with 10-year follow-up.

Authors:  Edwin A Takahashi; David F Kallmes; Kristin C Mara; William S Harmsen; Sanjay Misra
Journal:  Diagn Interv Radiol       Date:  2018-11       Impact factor: 2.630

Review 3.  Gadolinium-based contrast agents: why nephrologists need to be concerned.

Authors:  Katarina Leyba; Brent Wagner
Journal:  Curr Opin Nephrol Hypertens       Date:  2019-03       Impact factor: 2.894

Review 4.  Recent Advances in Magnetic Resonance Imaging Assessment of Renal Fibrosis.

Authors:  Jia Li; Changlong An; Lei Kang; William E Mitch; Yanlin Wang
Journal:  Adv Chronic Kidney Dis       Date:  2017-05       Impact factor: 3.620

5.  Nephrogenic Systemic Fibrosis Is Mediated by Myeloid C-C Chemokine Receptor 2.

Authors:  Catherine Do; Viktor Drel; Chunyan Tan; Doug Lee; Brent Wagner
Journal:  J Invest Dermatol       Date:  2019-04-09       Impact factor: 8.551

6.  Risk for Nephrogenic Systemic Fibrosis After Exposure to Newer Gadolinium Agents: A Systematic Review.

Authors:  Joseph Lunyera; Dinushika Mohottige; Anastasia-Stefania Alexopoulos; Hilary Campbell; C Blake Cameron; Nicole Sagalla; Timothy J Amrhein; Matthew J Crowley; Jessica R Dietch; Adelaide M Gordon; Andrzej S Kosinski; Sarah Cantrell; John W Williams; Jennifer M Gierisch; Belinda Ear; Karen M Goldstein
Journal:  Ann Intern Med       Date:  2020-06-23       Impact factor: 25.391

7.  Gadolinium-based contrast agents: Stimulators of myeloid-induced renal fibrosis and major metabolic disruptors.

Authors:  Catherine Do; Bridget Ford; Doug Yoon Lee; Chunyan Tan; Patricia Escobar; Brent Wagner
Journal:  Toxicol Appl Pharmacol       Date:  2019-05-10       Impact factor: 4.219

Review 8.  The prostate cancer focal therapy.

Authors:  Filippo Pesapane; Francesca Patella; Enrico Maria Fumarola; Edoardo Zanchetta; Chiara Floridi; Gianpaolo Carrafiello; Chloë Standaert
Journal:  Gland Surg       Date:  2018-04

9.  Gadolinium distribution in kidney tissue determined and quantified by micro synchrotron X-ray fluorescence.

Authors:  Wolf Osterode; Gerald Falkenberg; Heinz Regele
Journal:  Biometals       Date:  2021-01-23       Impact factor: 2.949

10.  Overlapping roles of NADPH oxidase 4 for diabetic and gadolinium-based contrast agent-induced systemic fibrosis.

Authors:  Francesca Bruno; Joshua DeAguero; Catherine Do; Doug Yoon Lee; Chunyan Tan; G Patricia Escobar; Brent Wagner
Journal:  Am J Physiol Renal Physiol       Date:  2021-02-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.